for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amneal Pharmaceuticals Inc

AMRX.N

Latest Trade

5.71USD

Change

-0.07(-1.21%)

Volume

167,930

Today's Range

5.71

 - 

5.88

52 Week Range

3.45

 - 

7.44

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5.78
Open
5.78
Volume
167,930
3M AVG Volume
41.97
Today's High
5.88
Today's Low
5.71
52 Week High
7.44
52 Week Low
3.45
Shares Out (MIL)
300.84
Market Cap (MIL)
1,738.84
Forward P/E
7.01
Dividend (Yield %)
--

Next Event

Amneal Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference (Virtual)

Latest Developments

More

Amneal Reports Q1 Adj Non-GAAP Earnings Per Share Of $0.20

Amneal Reports Fourth Quarter And Full Year 2020 Results

Amneal Pharmaceuticals Q3 Loss Per Share $0.06

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the developing, manufacturing, marketing and distributing high-value generic and branded specialty pharmaceutical products across a broad array of dosage forms and therapeutic areas. It operates in three segments, which include Generics, Specialty and AvKARE. The Generics segment provides prescription pharmaceutical products. The Specialty Pharma is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system (CNS) disorders. AvKARE segment provides pharmaceuticals, medical and surgical products and services to governmental agencies. Its other pipeline includes 505(b)(2) drugs and complex generics.

Industry

Biotechnology & Drugs

Contact Info

400 Crossing Blvd Fl 3

BRIDGEWATER, NJ

08807-2863

United States

+1.908.4096700

https://www.amneal.com/

Executive Leadership

Paul M. Meister

Independent Chairman of the Board

Chirag Patel

President, Co-Chief Executive Officer, Co-Founder, Director

Chintu Patel

Co-Chief Executive Officer, Co-Founder, Director

Anastasios G. Konidaris

Chief Financial Officer, Executive Vice President

Nikita Shah

Chief Human Resource Officer, Executive Vice President, Strategic Planning Officer

Key Stats

2.42 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.7K

2019

1.6K

2020

2.0K

2021(E)

2.1K
EPS (USD)

2018

0.980

2019

0.350

2020

0.630

2021(E)

0.805
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.88
Price To Book (MRQ)
5.38
Price To Cash Flow (TTM)
8.94
Total Debt To Equity (MRQ)
885.33
LT Debt To Equity (MRQ)
875.16
Return on Investment (TTM)
-1.16
Return on Equity (TTM)
-0.92

Latest News

Latest News

U.S. FTC sues Endo, Impax for 2017 agreement regarding pain drug

The U.S. Federal Trade Commission said on Monday it has filed a lawsuit against Endo Pharmaceuticals and Impax Laboratories that alleges a 2017 agreement eliminated competition between the companies for the pain medicine oxymorphone ER.

FTC sues Endo, Impax for 2017 agreement regarding pain drug

The U.S. Federal Trade Commission said on Monday it is filing a lawsuit against Endo Pharmaceuticals and Impax Laboratories which alleges a 2017 agreement eliminated competition between them for oxymorphone ER.

BRIEF-Amneal Launches Generic Fluphenazine Following ANDA Approval By FDA

* AMNEAL LAUNCHES GENERIC FLUPHENAZINE FOLLOWING ANDA APPROVAL BY FDA

Impax appeals FTC pay-for-delay ruling in opioid case

Impax Laboratories on Tuesday urged a federal appeals court to overturn the U.S. Federal Trade Commission's finding that it entered into an illegal pay-for-delay patent litigation settlement that delayed the release of a generic version of the opioid Opana ER.

BRIEF-Amneal Reports Q1 Adjusted Earnings Per Share $0.20

* Q1 REVENUE $499 MILLION VERSUS REFINITIV IBES ESTIMATE OF $446.1 MILLION

BRIEF-Amneal Launches Generic Butrans Following ANDA Approval By FDA

* AMNEAL LAUNCHES GENERIC BUTRANS® FOLLOWING ANDA APPROVAL BY FDA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Fed Circuit won't revisit Amgen patent win against Amneal

A federal appeals court on Wednesday declined to reconsider a recent decision that dealt a setback to Amneal Pharmaceuticals Inc in its bid to launch a generic version of the Amgen Inc drug Sensipar.

BRIEF-Amneal Accelerates Production Of Hydroxychloroquine Sulfate

* AMNEAL ACCELERATES DISTRIBUTION AND PRODUCTION OF HYDROXYCHLOROQUINE SULFATE TO MEET POTENTIAL NEEDS OF COVID-19 PATIENTS NATIONWIDE

BRIEF-Amneal Pharmaceuticals Appoints Tasos Konidaris As Senior Vice President, CFO

* AMNEAL PHARMACEUTICALS APPOINTS TASOS KONIDARIS AS SENIOR VICE PRESIDENT, CHIEF FINANCIAL OFFICER

Amneal cuts forecast as epinephrine shot supply issues linger, shares slump 36%

Shares of Amneal Pharmaceuticals Inc plunged 36% to an all-time low on Wednesday after the generic drugmaker cut its 2019 core earnings forecast due to supply uncertainties related to its epinephrine auto-injectors.

Amneal Pharma slashes core earnings forecast on allergy shot supply issues

Amneal Pharmaceuticals Inc on Wednesday cut its core earnings forecast for the year, citing uncertainty in supply of epinephrine auto-injectors amid a global shortage of the emergency allergy shots, including Mylan NV's EpiPen.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up